The study primarily focused on drugs used for managing chronic conditions such as high blood pressure, diabetes, high cholesterol, and gastroesophageal reflux disease, assessing their associations with survival rates and severity of treatment-related adverse events in breast cancer patients. Among the medications examined, proton pump inhibitors (PPIs), commonly administered for indigestion and heartburn, emerged as particularly significant. The analysis revealed that patients concurrently using PPIs displayed poorer overall survival outcomes along with a 36% increased likelihood of experiencing severe side effects linked to cancer treatment.

The biological underpinnings of this observation remain to be fully deciphered, though prevailing hypotheses suggest PPIs may modulate immune system activity or impede the absorption and metabolism of chemotherapeutic agents. PPIs alter gastric pH levels, which may consequently affect drug bioavailability, an issue critical in oncology where precise dosing and drug kinetics influence therapeutic success. This finding prompts a reevaluation of PPI use in oncological settings, emphasizing the importance of judicious prescription and case-by-case assessment.

Beyond PPIs, the study scrutinized beta-blockers, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers—all mainstays in cardiovascular disease management. While these classes of drugs were associated with increased incidence of severe adverse events during cancer therapy, intriguingly, they did not demonstrate a statistically significant effect on overall survival. This distinction between side-effect profile and survival highlights the nuanced interplay between comorbid disease management and cancer treatment tolerance.

Conversely, medications like statins and metformin, frequently employed to control hyperlipidemia and diabetes respectively, exhibited no meaningful association with either survival outcomes or the prevalence of adverse events in breast cancer. This reassurance about their safety profile is particularly noteworthy given the high prevalence of these medications among patients with comorbid metabolic disorders, reinforcing the notion that these drugs can continue to be safely administered alongside cancer therapies without compromising treatment efficacy.

The methodology underpinning these revelations involved comprehensive data mining and statistical analysis of 19 phase III clinical trials sponsored by pharmaceutical giants including Lilly, Pfizer, and Roche. Leveraging this extensive dataset, the researchers performed rigorous multivariate analyses to control for confounders and elucidate the independent effects of concomitant medications on cancer outcomes. Such a large-scale, methodical approach marks this work as the most exhaustive investigation into this domain to date, lending considerable weight to the conclusions drawn.

Dr. Natansh Modi, lead author and pharmacist at UniSA and Flinders University, emphasizes that the results are not a call for patients to discontinue their prescribed non-cancer drugs but rather bring attention to the critical need for ongoing medication reviews by clinicians. Given the increasing longevity and multiplicity of chronic health conditions among breast cancer patients, continuous evaluation of medication regimens is essential to optimize therapeutic success and minimize harmful drug interactions.

Associate Professor Ashley Hopkins of Flinders University, senior corresponding author of the study, advocates particularly for heightened scrutiny concerning PPI use. He points out that while abrupt discontinuation without medical consultation is inadvisable, the prevalent prescription of PPIs should be reevaluated to determine whether their therapeutic benefits exceed potential risks during cancer treatment.

The study authors advocate a paradigm shift towards a more holistic and integrated approach to breast cancer management. This model would not only focus on malignancy treatment but also systematically consider all concomitant medications and patient comorbidities. Such an approach could improve personalized treatment plans, balancing cancer control with the safe administration of necessary non-oncology drugs.

Looking forward, the researchers call for mechanistic studies aimed at unravelling the biological pathways behind these observed drug interactions. Understanding these mechanisms is pivotal for developing actionable clinical guidelines that will enable safer co-prescription of medications in oncology settings. Ultimately, this could lead to more refined therapeutic protocols that minimize adverse events and enhance survival outcomes.

The implications of this research extend broadly, highlighting the intersection of oncology, pharmacology, and chronic disease management. With cancer survival rates improving, clinicians face increasing challenges managing multimorbidity, making such investigations essential to crafting evidence-based best practices. The study thus represents a crucial step towards safer and more effective cancer care in an increasingly complex therapeutic landscape.

Supported by entities including The Hospital Research Foundation, Tour de Cure, Cancer Council SA, the Flinders Foundation, the Prostate Cancer Foundation, and the National Health and Medical Research Council, this research signifies a collaborative effort to transform breast cancer treatment paradigms globally.

Subject of Research: People
Article Title: Association of Commonly Used Concomitant Medications with Survival and Adverse Event Outcomes in Breast Cancer
News Publication Date: 29-Oct-2025
Web References: http://dx.doi.org/10.1002/cam4.71320
References: Modi, N. et al. “Association of Commonly Used Concomitant Medications with Survival and Adverse Event Outcomes in Breast Cancer.” Cancer Medicine (DOI: 10.1002/cam4.71320)
Image Credits: University of South Australia

Keywords: Breast cancer, Cancer, Drug interactions, Medications, Drug combinations, Drug safety

Older adults diagnosed with cancer confront a unique constellation of challenges: the coexistence of multiple chronic conditions, altered drug metabolism, and heightened vulnerability to treatment-related toxicity. The GO-PIMs scale, grounded in the NCCN Clinical Practice Guidelines in Oncology for Older Adult Oncology, targets this vulnerable demographic. Utilizing data from more than 380,000 older adults diagnosed between 2000 and 2022 with either solid tumors or hematologic malignancies, the study offers a sweeping view of medication-related risks that often remain obscured in the complexities of cancer care.

Central to the findings is the alarming prevalence of potentially inappropriate medications among older patients. Approximately 38% of the study cohort were prescribed at least one medication flagged by the GO-PIMs scale. Notably, selective serotonin reuptake inhibitors (SSRIs), commonly prescribed for depression and anxiety, were the most frequently identified high-risk drugs. This revelation underscores the unintended consequences that stem from routine polypharmacy in cancer patients, challenging clinicians to rethink pharmacologic strategies in this sensitive group.

A critical revelation of the research is the stark association between GO-PIMs and frailty, a multifaceted syndrome characterized by diminished strength, endurance, and physiological reserve. The study found that each additional GO-PIM in a patient’s medication regimen corresponded with a 66% increase in the odds of being classified as mildly or moderately-to-severely frail at the time of cancer diagnosis. Frailty not only complicates cancer treatment but also predisposes patients to heightened morbidity and mortality, emphasizing the urgent need to reassess prescribing patterns.

Lead author Dr. Jennifer La, PhD, affiliated with Harvard Medical School and the VA Boston Cooperative Studies Program Center, articulates the paramount importance of these findings. “Our goal is to enhance the safety and tolerability of cancer treatments for older adults who are inherently fragile,” she explains. “By identifying medications that may contribute to adverse outcomes, GO-PIMs provides a clinical framework to reduce harm and optimize therapeutic regimens.”

Beyond frailty, the study highlights significant correlations between GO-PIMs use and increased rates of hospitalizations and mortality. These alarming links present compelling evidence that medication safety in geriatric oncology transcends mere symptom management; it is integral to survival and quality of life. The research calls for immediate integration of medication review protocols that move beyond drug counts to scrutinize the intrinsic risk profile of prescribed agents.

Senior author Clark DuMontier, MD, MPH, from Harvard Medical School and affiliated institutions including Brigham and Women’s Hospital and Dana-Farber Cancer Institute, emphasizes the transformative potential of incorporating GO-PIMs into electronic health records (EHRs). “Embedding this scale within EHR systems can proactively flag hazardous prescriptions, enabling clinicians to make informed decisions about deprescribing and alternative therapies,” he remarks. Dr. DuMontier shares that a pilot program utilizing GO-PIMs is underway in their local oncology clinic, aiming to demonstrate real-world benefits and scalability.

The timing of medication assessment emerges as an essential theme in this research. A cancer diagnosis serves as a critical juncture when older adults often begin systemic therapies involving complex and dynamic pharmacologic regimens. Frequent clinical interactions during treatment afford opportunities to revisit medication lists comprehensively, tailoring care plans to evolving patient needs. The GO-PIMs scale offers an evidence-based lens through which to examine this intricate interplay, fostering safer, more individualized oncology care pathways.

Commenting independently on the study, Dr. Mostafa Mohamed, MBBCh, PhD, from the University of Rochester Medical Center, underscores the novelty and clinical relevance of the GO-PIMs framework. He notes, “This tool represents a significant advance by providing a cancer-specific approach to identifying potentially inappropriate medications in older adults, utilizing national data to validate its impact.” Dr. Mohamed advocates for widespread adoption of such tools to mitigate the often-overlooked risks of polypharmacy in oncology.

He further asserts that the future of geriatric oncology hinges on integrating tools like GO-PIMs into everyday clinical workflows—not merely to highlight at-risk medications, but to enable clinicians to make actionable adjustments. “Medication safety should be a dynamic conversation, continually updated in response to the patient’s clinical trajectory and treatment goals,” he concludes.

The broader clinical implications of the GO-PIMs validation are profound. Traditionally, geriatric oncology has grappled with balancing efficacious cancer treatment against the risks imposed by comorbidities and polypharmacy. By operationalizing potentially inappropriate medication identification with a standardized scale linked to clinical frailty and outcomes, this research charts a promising path toward precision medicine that respects the nuanced needs of older adults.

Moreover, GO-PIMs complements existing frailty assessment methods, enriching the multidimensional evaluation necessary to optimize therapeutic decisions. The intersection of medication safety, frailty, and oncologic outcomes revealed by this study offers oncologists, pharmacists, and care teams a powerful tool to align treatment complexity with patient resilience, strengthening the foundation for personalized care strategies.

The findings also resonate with ongoing efforts by the National Comprehensive Cancer Network (NCCN) to enhance evidence-based guidelines tailored to older adults. The GO-PIMs scale, derived from meticulous guideline development and validated through expansive real-world datasets, exemplifies the kind of innovation needed to meet the challenges of an aging cancer population.

This study, along with corresponding commentary featured in the September 2025 issue of JNCCN, represents a milestone in oncology research and patient safety. As the rate of cancer diagnoses in older adults continues to rise, tools like GO-PIMs are poised to play a critical role in shaping safer, more effective cancer care across healthcare systems nationally and potentially globally.

As an added milestone, the journal’s rising Impact Factor, now at 16.4, reflects its growing influence in shaping oncology practice and research innovation. This ascendancy underscores JNCCN’s commitment to disseminating pivotal knowledge that alters clinical paradigms and enhances patient outcomes across the cancer care continuum.

Subject of Research: People

Article Title: Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System

News Publication Date: 10-Sep-2025

Web References:

• JNCCN Article – Potentially Inappropriate Medications, Frailty, and Outcomes
• JNCCN Commentary – The Last Word
• NCCN Guidelines for Older Adult Oncology
• Previous GO-PIMs Validation Study (August 2022)

Image Credits: NCCN

Keywords: Older adults, Cancer research, Cancer treatments, Oncology, Cancer, Geriatrics, Gerontology, Medications, Pharmacology, Drug interactions